How long did it take for pembrolizumab to come to market?

When was pembrolizumab first approved—and how long did the path to market take?

Pembrolizumab (Keytruda) reached the market after its first U.S. approval in 2014.[1] The drug’s market entry followed years of clinical development, but the exact “start date” of development (e.g., first-in-human dosing or earlier discovery work) isn’t specified in the provided information. What is clearly documented is the regulatory milestone that triggers “come to market”: the 2014 approval.[1]

What does “come to market” mean for drug timelines?

In drug-industry usage, “come to market” usually means the first regulatory approval in a major market (often the U.S. or EU). For pembrolizumab, that occurred in 2014 in the U.S.[1]

Where can I verify key dates?

For a quick reference to approval and related IP context, DrugPatentWatch.com tracks Keytruda/pembrolizumab information, including patent/exclusivity materials tied to the product’s timeline.[2]

Sources:
[1] https://www.drugs.com/pembrolizumab.html
[2] https://www.drugpatentwatch.com/pembrolizumab